FilingReader Intelligence

Hubei Biocause Pharmaceutical to voluntarily delist from exchange

August 8, 2025 at 03:10 PM UTCBy FilingReader AI

Hubei Biocause Pharmaceutical will voluntarily delist from the Shenzhen Stock Exchange following a shareholder vote scheduled for August 25, 2025.

The company will offer dissenting shareholders a cash option of 1.60 yuan per share through Jingmen Weituo Hongcheng Management Partnership. The stock will transfer to the NEEQ's delisting board.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Hubei Biocause Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →